ArticleCancers2022
Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Exploratory multiomics analysis identifies WDR17 as a potential biomarker of tyrosine kinase inhibitor resistance in lung adenocarcinoma.Discover oncology · 2026Article
- Harnessing archaeogenetic for cancer therapy: bridging ancient DNA insights with modern therapeutic innovations.Clinical epigenetics · 2026Review
- Article
- Genomic profiling enables personalized strategies to overcome drug resistance in multiple myeloma.Discover oncology · 2026Review
- Molecular surveillance of the Plasmodium falciparum Pfmdr1 N86Y mutation linked to antimalarial drug resistance in Mbouda, Cameroon.Tropical diseases, travel medicine and vaccines · 2026Article
- Targeting the NAT10-HDAC4 positive feedback loop counteracts immunosuppression in breast cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- NAC1 Regulates PCK2 Expression and Activates Truncated Gluconeogenesis for Growth Advantage in Ovarian Cancer Cells.International journal of molecular sciences · 2025Article
- Redefining Chemoresistance: Natural Bioactives as Molecular Modulators at the Cancer-Tumor Microenvironment Interface.International journal of molecular sciences · 2025Review
- NAC1/ACOX2 Axis as a Novel Therapeutic Target for Endometriosis-Related Ovarian Neoplasms.International journal of molecular sciences · 2025Article
- Hydrogel-based nanoparticles: revolutionizing brain tumor treatment and paving the way for future innovations.European journal of medical research · 2025Review
- Recent Advancements in Breast Cancer Therapies and Biomarkers: Mechanisms and Clinical Significance.Current pharmaceutical biotechnology · 2025Review
- Administration of 2-deoxy-D-glucose induces pyroptosis in murine breast cancer cells via cAMP/PKA/HK2 to impair tumor survival.Frontiers in immunology · 2025Article
- Acyl Urea Compounds Therapeutics and its Inhibition for Cancers in Women: A Review.Anti-cancer agents in medicinal chemistry · 2025Review
- A Review of the Efficacy of Nanomaterial-Based Natural Photosensitizers to Overcome Multidrug Resistance in Cancer.Pharmaceutics · 2024Review
- The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target.Cancer cell international · 2024Review
- Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside.Frontiers in oncology · 2024Article
- How gallic acid regulates molecular signaling: role in cancer drug resistance.Medical oncology (Northwood, London, England) · 2023Review
- Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.Cancer metastasis reviews · 2023Review
- Cytotoxic and chemomodulatory effects of Phyllanthus niruri in MCF-7 and MCF-7Scientific reports · 2023Article
- The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer still represents a major global burden, being the second leading cause of death worldwide [...].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.